Payment overview · 2025
General Payments
$335.67
18 reported records · 9 companies
Healthcare provider profile · identity verified
Stephen Michael West, MD
Allopathic & Osteopathic Physicians|Family Medicine · EVERGREEN, AL · NPI 1588670475
Verified facts
What the public records show
CMS Open Payments records show Stephen Michael West, MD received $335.67 in general payments during 2025 across 18 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 21.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Vraylar by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 512 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 130 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 512 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 184 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 242 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $71.78 | 21.4% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $58.35 | 17.4% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $49.13 | 14.6% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $40.21 | 12.0% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $35.32 | 10.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $30.69 | 9.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.06 | 6.0% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $15.91 | 4.7% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.22 | 4.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $279.12 | 15 |
| Education | $56.55 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $87.50 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $58.35 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $49.13 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $40.21 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $35.32 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $20.06 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $20.06 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $15.91 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.97 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.97 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.22 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 242 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 512 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 101 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 130 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
142 | 35 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
512 | 87 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
130 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
512 | 87 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
101 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
184 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
242 | 37 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
20 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1017 | 266 |
| Pantoprazole Sodium | Pantoprazole Sodium | 803 | 225 |
| Amlodipine Besylate | Amlodipine Besylate | 785 | 210 |
| Potassium Chloride | Potassium Chloride | 672 | 163 |
| Metoprolol Succinate | Metoprolol Succinate | 550 | 151 |
| Jardiance | Empagliflozin | 512 | 87 |
| Furosemide | Furosemide | 501 | 130 |
| Metformin Hcl Er | Metformin Hcl | 497 | 141 |
| Gabapentin | Gabapentin | 470 | 81 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 416 | 103 |
| Levothyroxine Sodium | Levothyroxine Sodium | 387 | 83 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 370 | 78 |
| Lisinopril | Lisinopril | 338 | 99 |
| Meloxicam | Meloxicam | 332 | 82 |
| Ozempic | Semaglutide | 326 | 57 |
| Glipizide Er | Glipizide | 324 | 82 |
| Tamsulosin Hcl | Tamsulosin Hcl | 318 | 92 |
| Irbesartan | Irbesartan | 314 | 82 |
| Ezetimibe | Ezetimibe | 302 | 79 |
| Hydrochlorothiazide | Hydrochlorothiazide | 280 | 74 |
| Hydralazine Hcl | Hydralazine Hcl | 279 | 78 |
| Doxycycline Hyclate | Doxycycline Hyclate | 273 | 191 |
| Pravastatin Sodium | Pravastatin Sodium | 271 | 77 |
| Tramadol Hcl | Tramadol Hcl | 271 | 86 |
| Prednisone | Prednisone | 269 | 156 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 266 | 73 |
| Eliquis | Apixaban | 242 | 37 |
| Diclofenac Sodium | Diclofenac Sodium | 232 | 89 |
| Omeprazole | Omeprazole | 232 | 60 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 213 | 57 |
| Farxiga | Dapagliflozin Propanediol | 209 | 59 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 203 | 57 |
| Carvedilol | Carvedilol | 190 | 45 |
| Alprazolam | Alprazolam | 184 | 24 |
| Trulicity | Dulaglutide | 184 | 26 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 181 | 142 |
| Famotidine | Famotidine | 180 | 55 |
| Amoxicillin | Amoxicillin | 174 | 118 |
| Fluticasone Propionate | Fluticasone Propionate | 172 | 79 |
| Clopidogrel | Clopidogrel Bisulfate | 165 | 47 |
| Losartan Potassium | Losartan Potassium | 165 | 44 |
| Tizanidine Hcl | Tizanidine Hcl | 165 | 78 |
| Trazodone Hcl | Trazodone Hcl | 158 | 45 |
| Zolpidem Tartrate | Zolpidem Tartrate | 151 | 24 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 146 | 36 |
| Linzess | Linaclotide | 142 | 35 |
| Mirtazapine | Mirtazapine | 142 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 139 | 37 |
| Ibuprofen | Ibuprofen | 136 | 34 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 136 | 35 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 130 | 27 |
| Montelukast Sodium | Montelukast Sodium | 127 | 41 |
| Allopurinol | Allopurinol | 124 | 39 |
| Citalopram Hbr | Citalopram Hydrobromide | 121 | 31 |
| Clonidine Hcl | Clonidine Hcl | 119 | 33 |
| Xarelto | Rivaroxaban | 119 | 23 |
| Donepezil Hcl | Donepezil Hcl | 117 | 35 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 117 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 113 | 22 |
| Fenofibrate | Fenofibrate | 108 | 23 |
| Atenolol | Atenolol | 107 | 28 |
| Sertraline Hcl | Sertraline Hcl | 107 | 22 |
| Azithromycin | Azithromycin | 105 | 72 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 105 | 77 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 104 | 28 |
| Amitriptyline Hcl | Amitriptyline Hcl | 101 | 31 |
| Mounjaro | Tirzepatide | 101 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 99 | 23 |
| Levofloxacin | Levofloxacin | 99 | 79 |
| Klor-Con 10 | Potassium Chloride | 98 | 37 |
| Bupropion Xl | Bupropion Hcl | 97 | 25 |
| Meclizine Hcl | Meclizine Hcl | 95 | 39 |
| Fluconazole | Fluconazole | 88 | 44 |
| Lorazepam | Lorazepam | 88 | 18 |
| Ketoconazole | Ketoconazole | 82 | 30 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 80 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 80 | 19 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 77 | 35 |
| Pregabalin | Pregabalin | 77 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 75 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 75 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 72 | 14 |
| Clonazepam | Clonazepam | 71 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 70 | 25 |
| Simvastatin | Simvastatin | 70 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 70 | 46 |
| Lamotrigine | Lamotrigine | 68 | 13 |
| Estradiol | Estradiol | 66 | 19 |
| Ondansetron Odt | Ondansetron | 65 | 38 |
| Celecoxib | Celecoxib | 63 | 16 |
| Valacyclovir | Valacyclovir Hcl | 61 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 60 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 58 | 13 |
| Metformin Hcl | Metformin Hcl | 56 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 55 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 55 | suppressed |
| Levetiracetam | Levetiracetam | 54 | 12 |
| Buspirone Hcl | Buspirone Hcl | 52 | suppressed |
| Methocarbamol | Methocarbamol | 52 | 20 |
| Temazepam | Temazepam | 51 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 50 | 14 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 50 | 11 |
| Tresiba Flextouch U-200 | Insulin Degludec | 50 | 12 |
| Dexamethasone | Dexamethasone | 49 | 48 |
| Ibandronate Sodium | Ibandronate Sodium | 49 | 15 |
| Invokana | Canagliflozin | 49 | suppressed |
| Aripiprazole | Aripiprazole | 48 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 48 | 15 |
| Levemir Flexpen | Insulin Detemir | 45 | 11 |
| Sucralfate | Sucralfate | 45 | 26 |
| Terbinafine Hcl | Terbinafine Hcl | 45 | suppressed |
| Telmisartan | Telmisartan | 44 | 11 |
| Metronidazole | Metronidazole | 43 | 33 |
| Verapamil Er | Verapamil Hcl | 43 | suppressed |
| Finasteride | Finasteride | 41 | 13 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 41 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 40 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 38 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 37 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 36 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 35 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 34 | 22 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 34 | suppressed |
| Topiramate | Topiramate | 34 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 32 | suppressed |
| Glimepiride | Glimepiride | 32 | suppressed |
| Myrbetriq | Mirabegron | 31 | suppressed |
| Naproxen | Naproxen | 31 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 31 | suppressed |
| Nystatin | Nystatin | 28 | 15 |
| Cephalexin | Cephalexin | 27 | 19 |
| Creon | Lipase/Protease/Amylase | 27 | suppressed |
| Novolog Flexpen | Insulin Aspart | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Spironolactone | Spironolactone | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | 14 |
| Diltiazem Hcl | Diltiazem Hcl | 25 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Vascepa | Icosapent Ethyl | 24 | suppressed |
| Acyclovir | Acyclovir | 22 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Advair Diskus | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 18 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 18 | suppressed |
| Methimazole | Methimazole | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Bicalutamide | Bicalutamide | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Methotrexate | Methotrexate Sodium | 17 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Timolol Maleate | Timolol Maleate | 16 | suppressed |
| Vraylar | Cariprazine Hcl | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 15 | suppressed |
| Testosterone | Testosterone | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Kesimpta Pen | Ofatumumab | 13 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 12 | suppressed |
| Pentips Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 12 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $335.67 · 18 records | Boehringer Ingelheim Pharmaceuticals, Inc. | CAPLYTA, Cologuard Collection Kit, ELIQUIS, JARDIANCE, Kerendia, MOUNJARO, NURTEC ODT, TRELEGY ELLIPTA, VRAYLAR, ZEPBOUND, ZORYVE | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error